SequelSEC

Werewolf Therapeutics, Inc. HOWL

Pharmaceutical Preparations · CIK 0001785530 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$60.68M
Fiscal year ended 2025-12-31
Free cash flow
-$60.29M
Fiscal year ended 2025-12-31

Werewolf Therapeutics, Inc. (HOWL) reported net income of -$60.82M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from Werewolf Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Werewolf Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$60.68M-$73.59M-$40.50M-$56.06M-$50.09M-$22.40M
Net income-$60.82M-$70.52M-$37.37M-$53.81M-$49.98M-$15.04M
Research & development$44.83M$56.43M$41.78M$53.76M$35.27M$16.64M
Weighted-average diluted sharesshares 46.81Mshares 43.86Mshares 35.65Mshares 28.86Mshares 18.46Mshares 1.00M
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0UnavailableUnavailableUnavailableUnavailableUnavailable
Diluted EPS$-1.33$-1.63$-1.05$-1.86$-10.94$-28.08
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$15.85M$19.04M$18.67M$18.70M$14.82M$5.76M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Werewolf Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$57.05M$111.00M$134.34M$129.32M$157.53M$92.57M
Total assets$69.40M$126.93M$174.83M$160.24M$179.25M$96.40M
Current assets$58.59M$113.07M$138.37M$140.20M$161.07M$92.91M
Total liabilities$44.59M$53.54M$63.46M$37.91M$26.46M$7.18M
Current liabilities$36.15M$15.18M$19.38M$23.99M$11.87M$5.28M
Total equity incl. NCI$24.80M$73.39M$111.37M$122.34M$152.79M-$51.86M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$32.08M$32.08M$40.00MUnavailableUnavailableUnavailable
Accounts payable$754.00K$3.04M$1.34M$1.22M$2.04M$1.02M

Cash flow

Werewolf Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$60.29M-$56.19M-$32.61M-$40.60M-$42.88M-$18.62M
Capital expenditures$0$254.00K$769.00K$3.61M$498.00K$560.00K
Investing cash flow$0-$254.00K-$769.00K-$3.61M-$498.00K-$560.00K
Financing cash flow$6.03M$13.08M$58.43M$15.91M$109.43M$93.86M
Net change in cash-$54.26M-$43.36M$25.05M-$28.30M$66.05M$74.67M
Stock-based compensation$6.24M$8.83M$8.01M$7.40M$4.10M$632.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Werewolf Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flow-$60.29M-$56.44M-$33.38M-$44.21M-$43.37M-$19.18M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio1.62x7.45x7.14x5.84x13.56x17.58x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HOWL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-31View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-27View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2020-12-31

Difference 141082000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.